Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Convention
October 05 2021 - 8:00AM
Business Wire
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage,
next-generation gene editing company focused on therapies that
harness targeted gene integration to treat or cure serious
diseases, today announced an abstract related to the company’s
sickle cell disease (SCD) research has been accepted for poster
presentation during the 49th Annual Sickle Cell Disease Association
of America (SCDAA) National Convention, taking place virtually
Oct.12-16, 2021.
Details of Graphite Bio’s poster presentation are as
follows:
Poster Session: Basic Science and Translational Research
Abstract: Preclinical Data in Support of CEDAR, A Phase 1/2
Study of Ex-Vivo Autologous Gene Corrected (HbS to HbA)
Hematopoietic Stem Cells to Treat Severe Sickle Cell Disease
Presenter: Premanjali Lahiri, Director, Process Development
at Graphite Bio Date/Time: October 12 at 1-2 p.m. ET
About Sickle Cell Disease (SCD)
SCD is a serious, life-threatening inherited blood disorder that
affects approximately 100,000 people in the United States and
millions of people around the world, making it the most prevalent
monogenic disease worldwide. SCD is caused by a single mutation in
the beta-globin gene that leads to red blood cells that are
responsible for delivering oxygen to tissues and organs throughout
the body to become misshapen, resulting in anemia, blood flow
blockages, intense pain, increased risk of stroke and organ damage,
and reduced life span of approximately 30 years. Despite
advancements in treatment and care, progressive organ damage
continues to cause early mortality and severe morbidity,
highlighting the need for curative therapies.
About GPH101
GPH101 is an investigational next-generation gene-edited
autologous hematopoietic stem cell (HSC) therapy designed to
directly correct the genetic mutation that causes sickle cell
disease (SCD). GPH101 is the first investigational therapy to
utilize a highly differentiated gene correction approach that seeks
to efficiently and precisely correct the mutation on the
beta-globin gene to decrease sickle hemoglobin (HbS) production and
restore normal adult hemoglobin (HbA) expression, thereby
potentially curing SCD.
Graphite Bio is evaluating GPH101 in the CEDAR trial, an
open-label, multi-center Phase 1/2 clinical trial designed to
assess the safety, engraftment success, gene correction rates,
total hemoglobin, as well as other clinical and exploratory
endpoints and pharmacodynamics in patients with severe SCD.
About Graphite Bio
Graphite Bio is a clinical-stage, next-generation gene editing
company harnessing high efficiency precision gene correction to
develop a new class of therapies to potentially cure a wide range
of serious and life-threatening diseases. Graphite Bio is
pioneering a precision gene editing platform that could enable a
variety of applications to transform human health and achieve one
of medicine’s most elusive goals: to precisely “find & replace”
any gene in the genome. Graphite Bio’s platform allows it to
precisely correct mutations, replace entire disease-causing genes
with normal genes, or insert new genes into predetermined, safe
locations. The company was co-founded by academic pioneers in the
fields of gene editing and gene therapy, including Maria Grazia
Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.
Learn more about Graphite Bio by visiting www.graphitebio.com
and following the company on LinkedIn.
Forward-Looking Statements
Statements we make in this press release may include statements
which are not historical facts and are considered forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended (the “Securities Act”), and Section 21E of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”).
These statements may be identified by words such as “aims,”
“anticipates,” “believes,” “could,” “estimates,” “expects,”
“forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”
“potential,” “seeks,” “will,” and variations of these words or
similar expressions that are intended to identify forward-looking
statements. Any such statements in this press release that are not
statements of historical fact, including statements regarding the
clinical and therapeutic potential of our gene editing platform and
our product candidates, and the timing for enrollment of the first
patient in our Phase 1/2 clinical trial of GPH101 and the
availability of initial proof-of-concept data, may be deemed to be
forward-looking statements. We intend these forward-looking
statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 27A of the
Securities Act and Section 21E of the Exchange Act and are making
this statement for purposes of complying with those safe harbor
provisions.
Any forward-looking statements in this press release are based
on Graphite Bio’s current expectations, estimates and projections
only as of the date of this release and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements, including the risk that we may
encounter delays in patient enrollment and in the initiation,
conduct and completion of our planned clinical trials. These risks
concerning Graphite Bio’s programs and operations are described in
additional detail in its periodic filings with the SEC, including
its quarterly report on Form 10-Q filed with the SEC on August 12,
2021. Graphite Bio explicitly disclaims any obligation to update
any forward-looking statements except to the extent required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211005005319/en/
Company Contact: Stephanie Yao VP, Communications and
Investor Relations 443-739-1423 syao@graphitebio.com
Investor Relations: Stephanie Ascher Stern IR, Inc.
212-362-1200 ir@graphitebio.com
Media Contact: Christy Curran Sam Brown, Inc.
615-414-8668 media@graphitebio.com
Graphite Bio (NASDAQ:GRPH)
Historical Stock Chart
From May 2024 to Jun 2024
Graphite Bio (NASDAQ:GRPH)
Historical Stock Chart
From Jun 2023 to Jun 2024